Ninerafaxstat

About Imbria Pharmaceuticals

Imbria Pharmaceuticals is a private, clinical-stage biotechnology company pioneering a novel approach to cardiovascular disease by targeting cardiac energy metabolism. Its lead asset, ninerafaxstat, is in Phase 2b development for non-obstructive hypertrophic cardiomyopathy (nHCM) and has shown promise in Phase 2a trials for cardiometabolic heart failure with preserved ejection fraction (HFpEF). The company is well-capitalized following a $57.5 million Series B financing extension in late 2025 and is led by a seasoned management team with deep cardiovascular and drug development expertise.

About Imbria Pharmaceuticals

Imbria Pharmaceuticals is a private, clinical-stage biotechnology company pioneering a novel approach to cardiovascular disease by targeting cardiac energy metabolism. Its lead asset, ninerafaxstat, is in Phase 2b development for non-obstructive hypertrophic cardiomyopathy (nHCM) and has shown promise in Phase 2a trials for cardiometabolic heart failure with preserved ejection fraction (HFpEF). The company is well-capitalized following a $57.5 million Series B financing extension in late 2025 and is led by a seasoned management team with deep cardiovascular and drug development expertise.

About Imbria Pharmaceuticals

Imbria Pharmaceuticals is a private, clinical-stage biotechnology company pioneering a novel approach to cardiovascular disease by targeting cardiac energy metabolism. Its lead asset, ninerafaxstat, is in Phase 2b development for non-obstructive hypertrophic cardiomyopathy (nHCM) and has shown promise in Phase 2a trials for cardiometabolic heart failure with preserved ejection fraction (HFpEF). The company is well-capitalized following a $57.5 million Series B financing extension in late 2025 and is led by a seasoned management team with deep cardiovascular and drug development expertise.

Therapeutic Areas